National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rimegepant (Vydura®). HTA ID: 22051

Rimegepant is indicated for the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

 

NCPE Assessment Process Complete
Rapid review commissioned 13/07/2022
Rapid review completed 12/09/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care.